Saisheng Pharmaceutical: Announcement on the inclusion of the company and its subsidiary products in the "National Essential Drugs List (2026 Edition)"
Securities code: 300485 Securities abbreviation: Saisheng Pharmaceutical Announcement number: 2026-025
Beijing Saisheng Pharmaceutical Co., Ltd.
Announcement on the inclusion of the company and its subsidiary products in the "National Essential Drugs List (2026 Edition)"
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Recently, the National Health Commission, the State Administration of Traditional Chinese Medicine, and the National Administration of Disease Control and Prevention jointly issued the "Notice on Printing and Issuing the National Essential Drugs List (2026 Edition)" (National Health Drug Administration [2026] No. 17). According to statistics, Beijing Saisheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), its subsidiary Shenyang Junyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Shenyang Junyuan"), and its holding subsidiary Beijing Saiers Biopharmaceutical Co., Ltd. (hereinafter referred to as "Sersheng Biopharmaceuticals") have added 2 new varieties to the national essential medicine catalog. The relevant information is now announced as follows:
Serial number Number Variety name Specification Manufacturer
Beijing Saisheng Pharmaceutical Co., Ltd.
1 296 Urokinase for injection 100,000 units
Co., Ltd.
0.1g (according to Beijing Saier Biopharmaceuticals
2 13 Cefixime tablets
C16H15N5O7S2 Design) Industry Co., Ltd.
Impact on the company:
This time, the company's products are included in the "2026 Edition of the Essential Drugs Catalog." This matter is not expected to have a major impact on the company's operations in the short term. It will have a positive effect on the company's future expansion of the product market and sales, as well as the company's long-term development. Investors are advised to invest rationally and pay attention to investment risks.
Announcement hereby
Beijing Saisheng Pharmaceutical Co., Ltd.
July 10, 2026